PENTAGASTRIN solution

Šalis: Jungtinės Valstijos

kalba: anglų

Šaltinis: NLM (National Library of Medicine)

Veiklioji medžiaga:

PENTAGASTRIN (UNII: EF0NX91490) (PENTAGASTRIN - UNII:EF0NX91490)

Prieinama:

AnazaoHealth Corporation

INN (Tarptautinis Pavadinimas):

PENTAGASTRIN

Sudėtis:

PENTAGASTRIN 250 ug in 1.6 mL

Vartojimo būdas:

INTRAVENOUS

Recepto tipas:

PRESCRIPTION DRUG

Terapinės indikacijos:

- Anacidity (diagnosis) —Pentagastrin is indicated as a diagnostic aid for evaluation of gastric acid secretory function. It is effective in testing for anacidity (achlorhydria) in patients with suspected pernicious anemia, atrophic gastritis, or gastric carcinoma. It is also effective in determining the reduction in acid output after operations for peptic ulcer, such as vagotomy or gastric resection. - Hypersecretory conditions, gastric (diagnosis) —Pentagastrin is indicated as a diagnostic aid in testing for gastric hypersecretion in patients with suspected duodenal ulcer or postoperative stomal ulcer, and for the diagnosis of Zollinger-Ellison tumor

Autorizacija statusas:

unapproved drug other

Prekės savybės

PENTAGASTRIN - PENTAGASTRIN SOLUTION
ANAZAOHEALTH CORPORATION
_Disclaimer: This drug has not been found by FDA to be safe and
effective, and this labeling has not been_
_approved by FDA. For further information about unapproved drugs,
click here._
----------
PENTAGAS TRIN
DESCRIPTION
Pentagastrin, a diagnostic aid, is supplied as a sterile solution (1.1
ml/5 ml vial) containing:
250 micrograms Pentagastrin per ml
0.8 mg Methylparaben and 0.2 mg Propylparaben per mL
0.9 mg sodium chloride per mL
pH 8
CLINICAL PHARMACOLOGY
The exact mechanism by which Pentagastrin stimulates gastric acid,
pepsin, and intrinsic factor
secretion is unknown; however, since Pentagastrin is an analogue of
natural gastrin, it is believed that it
excites the oxyntic cells of the stomach to secrete to their maximum
capacity. Pentagastrin stimulates
pancreatic secretion, especially when administered in large
intramuscular doses. Pentagastrin also
increases gastrointestinal motility by a direct effect on the
intestinal smooth muscle. However, it delays
gastric emptying time probably by stimulation of terminal antral
contractions, which enhance
retropulsion.
OTHER ACTIONS/EFFECTS Pentagastrin increases blood flow in the gastric
mucosa, inhibits
absorption of water and electrolytes from the ileum, and promotes
sodium and chloride diuresis. It
causes contraction of the smooth muscle of the lower esophageal
sphincter when administered
intravenously. Pentagastrin produces an increase in the motor activity
of the colon and rectum
ONSET OF ACTION 10 minutes
TIME TO PEAK EFFECT 20 to 30 minutes
DURATION OF ACTION 60 to 80 minutes
INDICATIONS AND USAGE
1. ANACIDITY (DIAGNOSIS)—Pentagastrin is indicated as a diagnostic
aid for evaluation of gastric acid
secretory function. It is effective in testing for anacidity
(achlorhydria) in patients with suspected
pernicious anemia, atrophic gastritis, or gastric carcinoma. It is
also effective in determining the
reduction in acid output after operations for peptic ulcer, such as
vagotomy or gastric resection